Acura Pharmaceuticals receives $200,000 in new loans from AD Pharma

Acura Pharmaceuticals , Inc. (OTC:ACUR), with a current market capitalization of just $170,000, disclosed Tuesday that it has received two loans totaling $200,000 from Abuse Deterrent Pharma, LLC (AD Pharma) on June 3 and June 20. According to a statement based on a Securities and Exchange Commission filing, these new loans add to previous borrowings, bringing the total principal balance under the company’s November 10, 2022, Amended Consolidated and Restated Secured Promissory Note to $8,194,279 as of June 20. Accrued interest on this debt is approximately $721,000.

The loans bear interest at an annual rate of 5.25%. If any payment is missed and remains unpaid for five days, the overdue amount will accrue interest at a rate of 7.5% per year until paid in full. Events that could trigger default under the note include bankruptcy and failure to pay interest or principal when due.

Acura stated that the funding from AD Pharma will be used for day-to-day operations. The company also noted that if it does not secure additional financing by mid-July 2025, it may be required to scale back operations, furlough or lay off employees, or potentially terminate operations and seek bankruptcy protection. According to InvestingPro data, the company’s financial health score stands at a concerning 1.34, rated as "WEAK," with several indicators pointing to financial stress. InvestingPro subscribers have access to 8 additional key financial health indicators for ACUR.

As of May 31, 2025, AD Pharma directly owned approximately 65% of Acura’s outstanding common stock, not including a warrant to purchase an additional 10 million shares. AD Pharma is controlled by Mr. Schutte, who is also the managing partner and investor. Mr. Schutte directly owns about 13% of Acura’s outstanding common stock.

The company’s common stock trades on the OTC Expert Market under the symbol ACUR.

This report is based on a statement contained in a recent SEC filing.

In other recent news, Acura Pharmaceuticals has reported notable progress in the development of its drug candidate, LTX-03. The company, in collaboration with Abuse Deterrent Pharma, LLC, held discussions with the U.S. Food and Drug Administration (FDA) regarding the advancement of LTX-03 towards a New Drug Application (NDA) submission. LTX-03 utilizes Acura’s LIMITx technology, which aims to reduce the peak blood concentration of hydrocodone when multiple tablets are ingested, thereby mitigating risks associated with opioid overdose. The FDA was open to including the unique pharmacokinetic features of LTX-03 in the final approved labeling but advised that a label claim for a lower risk of overdose would not be justified solely based on pharmacokinetic testing. Acura plans to conduct an additional human pharmacokinetic study, AP-LTX-310, which will compare a single tablet dose of LTX-03 to an FDA Reference Standard drug. This study is contingent upon the production of new clinical supplies of LTX-03. The FDA also recommended that scientific support be provided for the lower dosage strengths of LTX-03 in the NDA. Acura is considering whether to include this study in the NDA submission or to add it after approval.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.